Thalidomide plus standard chemo and cetuximab for left-sided colon cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding the drug thalidomide to standard chemotherapy plus cetuximab can work better for people with advanced left-sided colorectal cancer that hasn't been treated before. If you have a specific gene type (RAS/BRAF wild-type) and are in generally good health, this study may be an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your colorectal cancer is on the left side and has spread to other parts of the body (Stage IV).
- The tumor has no mutations in the RAS or BRAF genes (called 'wild-type').
- You are between 18 and 75 years old.
- You have not had chemotherapy or cetuximab before.
- Your liver, kidney, and bone marrow function are mostly normal.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether adding cetuximab to irinotecan can control metastatic colorectal cancer that has returned or worsened after standard treatments. It targets people whose tumor is left-sided and shows “wild-type” RAS and BRAF genes on blood testing after prior therapy.
This study compares two different combinations of chemotherapy plus a targeted therapy called cetuximab as a first treatment for a specific type of advanced colorectal cancer. The goal is to see which combination works better and has fewer side effects.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy and a targeted therapy (cetuximab) as the first treatment for colorectal cancer that has come back or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of three drugs (cetuximab, irinotecan, and toripalimab) for people with advanced right-sided colon cancer that does not have certain gene mutations. It's for those whose cancer has gotten worse after standard treatments.
This Phase 2 trial tests a combination of medicines (cetuximab, envafolimab, and chemotherapy) as the first treatment for certain left-sided metastatic colorectal cancers. It may help by slowing or shrinking the cancer in people whose tumor has no RAS/BRAF mutations and is microsatellite-stable (MSS).
This trial is testing a new combination of three drugs (cetuximab, envolimab, and a chemo called mFOLFOX6) for people with advanced colorectal cancer that has not been treated yet. The goal is to see if this combination is safe and works better than standard treatments.
Hear when a new Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.